Dr. V Prasada Raju resigns as MD; Mr. Himanshu Agarwal appointed Whole-time Director & CFO
Cohance Lifesciences announces the resignation of MD Dr. V Prasada Raju, effective October 28, 2025. Mr. Himanshu Agarwal, CFO, is appointed Whole-time Director and CFO from October 29, 2025, subject to shareholder approval.
Changes in the Managing Director and the appointment of the Chief Financial Officer to a Whole-time Director position are significant leadership changes. However, the internal promotion and the stated smooth transition mitigate the potential negative impact, leading to a medium impact on the company's operations and strategy.
The announcement involves both a resignation of a key management personnel (MD) and the appointment of another (CFO to Whole-time Director & CFO). While a resignation could be seen negatively, the immediate appointment of an internal, experienced professional for a critical role, along with the mention of a seamless transition, balances the overall sentiment to neutral.
* The Board of Directors of Cohance Lifesciences Limited, at its meeting held on October 28, 2025, noted the resignation of Dr. V Prasada Raju (DIN: 07267366) as Managing Director and Director of the Company. His resignation is effective from the close of business hours on October 28, 2025. He will continue to be available to facilitate a seamless transition of his duties. * The Board appreciated Dr. V Prasada Raju's valuable contribution during his tenure. * Based on the Nomination and Remuneration Committee's recommendations, the Board approved the appointment of Mr. Himanshu Agarwal (DIN: 06672915), currently the Chief Financial Officer, as an Additional Director. He is appointed for a period of five years, effective from October 29, 2025, and will be designated as Whole-time Director and Chief Financial Officer. * This appointment is subject to the approval of the company's shareholders through a postal ballot process. * Mr. Himanshu Agarwal is a finance professional with over 30 years of experience, having previously worked with MNCs like ICI India, Huhtamaki oyj, AkzoNobel India, Astra Zeneca Pharma Ltd, and Bennett, Coleman & Co. * The company also approved revisions to the authorized Key Managerial Personnel for determining materiality of events and making disclosures, effective from October 29, 2025. The updated KMP includes Mr. Vivek Sharma (Executive Chairman), Mr. Himanshu Agarwal (Whole-time Director and Chief Financial Officer), and Mr. Kundan Kumar Jha (Company Secretary, Compliance Officer and Head-Legal).
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.